RTP Mobile Logo

Thursday, May 17, 2018, Washington, DC, 6:00 AM – 7:30 AM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A CNE Symposia Series Held During the 43rd Annual ONS Congress

PART 2 — Gastrointestinal Cancers

Event Details

Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence A-E (Meeting Level 4)
Schedule (EST):
5:30 AM – 6:00 AM
Registration and Breakfast Buffet

6:00 AM – 7:30 AM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Co-Leader, GI Cancer Program
Mayo Clinic Cancer Center
Senior Associate Consultant
Mayo Clinic
Scottsdale, Arizona

Michael Casey, APRN-BC, FNP
Gastrointestinal Cancer Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

John L Marshall, MD
Chief, Hematology and Oncology
Director, Ruesch Center for the Cure of GI Cancers
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Jessica Mitchell, APRN, CNP, MPH
Assistant Professor, GI Oncology
Mayo Clinic
Rochester, Minnesota

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a symposium supported by Celgene Corporation, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Merck and Taiho Oncology Inc during the Oncology Nursing Society’s (ONS) 43rd Annual Congress, May 16-20, 2018 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.


Module 1: Pancreatic Cancer


  • Current role of chemotherapy, including FOLFIRINOX and gemcitabine/nab paclitaxel, in the neoadjuvant, adjuvant and metastatic settings
  • Importance of age, performance status and symptomatology in the selection of first-line therapy for patients with metastatic pancreatic cancer
  • Management of side effects associated with currently available agents; palliative considerations in advanced pancreatic cancer
  • Mechanism of action of and available research data with nanoliposomal irinotecan (nal-IRI)
  • Integration of nal-IRI/5-FU into the management of metastatic disease
  • Patient education issues in the use of nal-IRI; amelioration of associated gastrointestinal and hematologic toxicities
  • Agents and treatment strategies currently in development

Module 2: Gastric Cancer


  • Evidence-based integration of ramucirumab into clinical algorithms for metastatic gastric/gastroesophageal junction (GEJ) cancer; ongoing clinical trials of ramucirumab
  • Management of hypertension and other anti-angiogenic class-related side effects of ramucirumab
  • Recent FDA approval of pembrolizumab for patients with recurrent locally advanced or metastatic gastric or GEJ adenocarcinoma and a combined positive score of 1 or higher
  • Available clinical trial data with and ongoing research evaluating other anti-PD-1/PD-L1 antibodies for metastatic gastric/GEJ cancer
  • Supportive care approaches to ameliorate side effects associated with anti-PD-1/PD-L1 antibodies
  • Other promising agents and strategies being evaluated in Phase III studies

Module 3: Colorectal Cancer (CRC)


  • Indications for microsatellite instability (MSI) testing in metastatic CRC (mCRC)
  • FDA approvals of the anti-PD-1 antibodies pembrolizumab and nivolumab for MSI-high or mismatch repair-deficient mCRC
  • Biologic rationale for and ongoing trials evaluating immune checkpoint inhibitors in combination with other systemic agents for patients with microsatellite-stable mCRC
  • Factors affecting the sequencing of TAS-102 and regorafenib for patients with mCRC
  • Optimal dosing of regorafenib; strategy of dose escalation versus dose reduction
  • Amelioration of hand-foot syndrome and hypertension associated with regorafenib
  • Mechanism of action of TAS-102; integration into the treatment algorithm
  • Management of neutropenia associated with TAS-102 and correlation with response

Module 4: Hepatocellular Carcinoma (HCC)


  • Monitoring and management of disease symptoms observed in patients with advanced HCC
  • Local treatment approaches for HCC: liver resection, transarterial chemoembolization, radiofrequency ablation
  • Integration of the tyrosine kinase inhibitor (TKI) sorafenib into the care of patients with advanced HCC; optimal dosing; management of side effects
  • Considerations in the selection of regorafenib (TKI) or nivolumab (anti-PD-1 antibody) as second-line treatment for patients experiencing disease progression on sorafenib
  • Phase III clinical research data evaluating the TKIs lenvatinib and cabozantinib in advanced HCC
  • Ongoing trials evaluating other immune checkpoint inhibitors in HCC

CE Information

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gastrointestinal (GI) cancers.

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Apply available research data to the therapeutic and supportive care of patients with pancreatic cancer, gastric/gastroesophageal junction (GEJ) cancer, colorectal cancer (CRC) and hepatocellular carcinoma (HCC).
  • Consider age, performance status and other clinical and logistical factors in the selec-tion of systemic therapy for patients with localized, locally advanced or metastatic pancreatic cancer.
  • Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to optimize systemic therapy for locally advanced or metastatic gastric/GEJ cancer.
  • Recognize the importance of biomarker analysis for patients diagnosed with CRC or gastric/GEJ cancer, and use this information to counsel these individuals regarding the selection of evidence-based systemic treatment options.
  • Describe the clinical indications, benefits and toxicities associated with the use of existing and recently approved systemic therapies in the management of metastatic CRC.
  • Communicate the benefits and risks of approved and emerging systemic interventions to patients with locally advanced or metastatic HCC.
  • Appraise the rationale for and clinical data with commercially available and developmental immune checkpoint inhibitors in the treatment of GI cancers.
Accreditation Statement:
Research To Practice (RTP) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements:
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information:
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2018/ILNA

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP staff and external reviewers — The scientific staff, planners and managers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Celgene Corporation, Eisai Inc, Exelixis Inc, Ipsen Biopharmaceuticals Inc, Merck and Taiho Oncology Inc.


Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room: 
Independence A-E (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2018 ONS Congress and provides direct access to the Walter E Washington Convention Center via an underground concourse.



Thank you for your interest in our CNE symposia series. At this time, online preregistration is closed for PART 2 — GI Cancers. Onsite registration will be open starting at 5:30 AM (ET) on Thursday, May 17th.

If you are interested in standing by for seating (day of the program), please visit our registration desk located outside Independence A-E, Ballroom (Meeting Level 4) at the Marriott Marquis Washington, DC (901 Massachusetts Ave NW, Washington, DC 20001). You may arrive up to 45 minutes before the program start time and receive a standby ticket.

If seats become available for the program, we will accept standby registration on a first come, first served basis. Please note, onsite registration does not guarantee participation in the session or meal service. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME/CNE programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.